David A. Siegel Rallybio Corp Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Rallybio Corp stock. As of the latest transaction made, Two Sigma Advisers, LP holds 88,900 shares of RLYB stock, worth $47,117. This represents 0.0% of its overall portfolio holdings.
Number of Shares
88,900
Previous 91,020
2.33%
Holding current value
$47,117
Previous $59,000
49.15%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding RLYB
# of Institutions
49Shares Held
31.6MCall Options Held
0Put Options Held
0-
Viking Global Investors LP4.19MShares$2.22 Million0.0% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.64MShares$1.93 Million0.42% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA3.63MShares$1.92 Million0.83% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY3.3MShares$1.75 Million3.34% of portfolio
-
Tpg Gp A, LLC Fort Worth, TX3.03MShares$1.61 Million0.06% of portfolio
About Rallybio Corp
- Ticker RLYB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 32,132,000
- Market Cap $17M
- Description
- Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of feta...